Weekly Competitor News Sweep

BlueRock advanced bemdaneprocel to a registrational Phase III — the first for any pluripotent-stem-cell-derived therapy in Parkinson's. TreeFrog presented preclinical data showing functional motor recovery in ~13 weeks.